Vancouver, BC – In a landmark achievement that heralds a new era in personalized cancer medicine, a pan-Canadian team of researchers has pioneered a revolutionary approach to rapidly identify tailored treatments for young cancer patients. By harnessing the unexpected power of chicken eggs to host patient tumours and meticulously analyzing their proteins, the team has successfully intervened in a case where conventional and genomics-driven therapies had failed, offering renewed hope for children battling aggressive and rare cancers.
This groundbreaking methodology, spearheaded by investigators from the University of British Columbia (UBC) and BC Children’s Hospital Research Institute (BCCHR), marks the first instance in Canada where the synergistic combination of tumour avatars grown in eggs and advanced proteomics analysis has led to the identification and validation of a life-saving drug for a young patient within a clinically relevant timeframe. The success of this innovative strategy, detailed today in the prestigious journal EMBO Molecular Medicine, underscores the critical role that the comprehensive study of proteins – known as proteomics – can play as an invaluable complement to the established field of genomics in the urgent pursuit of real-time cancer therapies.
The collaborative spirit driving this monumental effort is embodied by PROFYLE (PRecision Oncology For Young peopLE), a flagship initiative of the Canadian pediatric cancer network ACCESS (Advancing Childhood Cancer Experience, Science and Survivorship). This expansive network unites over 30 research and funding organizations and more than 100 investigators from across Canada, all committed to a singular, vital mission: dramatically improving cancer outcomes for children, adolescents, and young adults facing some of the most challenging diagnoses.
The pivotal study, co-led by Dr. Georgina Barnabas, a postdoctoral researcher in Dr. Philipp Lange’s laboratory, and Tariq Bhat, a PhD student in Dr. James Lim’s laboratory, centered on an unnamed pediatric patient diagnosed with an exceptionally rare and aggressive form of cancer that had proven stubbornly resistant to all conventional treatment modalities. Their journey, from diagnostic uncertainty to therapeutic discovery, illuminates the path forward for countless other young lives.
The Unmet Need in Pediatric Oncology: A Race Against Time
Pediatric cancer, while relatively rare compared to adult cancers, presents a unique and formidable challenge. Childhood cancers are often biologically distinct, more aggressive, and can spread rapidly. Moreover, the developing bodies of children are highly susceptible to the long-term, debilitating side effects of traditional treatments like chemotherapy and radiation, which can impact their growth, fertility, cognitive function, and increase their risk of secondary cancers later in life. This urgent need for more targeted, less toxic therapies has propelled the field of personalized medicine to the forefront.
For years, precision oncology has largely been driven by genomics – the study of an individual’s genes. By sequencing a tumour’s DNA, researchers aim to identify specific genetic mutations that might be driving the cancer’s growth and then match these mutations to targeted drugs. This approach has yielded significant successes in some adult cancers and a subset of pediatric cases. However, as the case of the unnamed patient illustrates, genomics alone often falls short.
"Despite significant advancements in genomic sequencing, there remains a substantial cohort of patients, particularly in the pediatric oncology setting, for whom genetic testing does not reveal a clear, actionable target," explains Dr. Rebecca Deyell, a clinician and senior investigator with the Michael Cuccione Childhood Cancer Research Program at BCCHR, who was part of the senior investigative team. "These are often patients with highly aggressive or rare cancers, where every moment counts, and the inability to find a precise treatment option can be devastating." The limitations of genomics stem from the fact that while genes provide the blueprint, proteins are the actual workhorses of the cell, carrying out all biological functions. Most drugs, in fact, exert their therapeutic effects by interacting directly with proteins. Therefore, focusing solely on genetic mutations might miss crucial vulnerabilities at the protein level.
Chronology of a Breakthrough: From Resistance to Revelation
The unnamed patient’s journey began with a diagnosis of a rare pediatric cancer, a battle that quickly escalated as standard chemotherapy regimens proved ineffective. With the tumour relentlessly progressing, the medical team turned to advanced genomic testing, hoping to uncover a genetic Achilles’ heel. Initially, genomics did identify a potential drug candidate, but even this targeted therapy ultimately failed, and the tumour developed resistance, leaving the patient with no clear treatment path. This grim prognosis underscored the urgent need for an alternative strategy.
It was at this critical juncture that the team, led by senior investigators Dr. Lange and Dr. Lim, pivoted to proteomics. Their hypothesis was compelling: if proteins are the functional molecules targeted by drugs, then a detailed map of the tumour’s protein landscape might reveal vulnerabilities that genomics had overlooked.
"With genomics alone, we couldn’t find a clear treatment option," said Dr. Lange, who, along with Dr. Lim and Dr. Deyell, are senior investigators with the Michael Cuccione Childhood Cancer Research Program at BCCHR. "But by looking at the tumour’s proteins, we found a critical metabolic weakness that we could target with an already approved drug."
Through meticulous proteomic analysis, the researchers uncovered a profound reliance of the patient’s tumour metabolism on a specific enzyme: SHMT2 (Serine Hydroxymethyltransferase 2). This enzyme plays a crucial role in cellular metabolism, particularly in the synthesis of nucleotides and amino acids, which are essential building blocks for rapidly dividing cancer cells. Inhibiting SHMT2, the team reasoned, could effectively starve the tumour of a key energy source and impede its growth.
The next step was to identify a drug that could specifically target SHMT2. Through a combination of literature review and computational modeling, the researchers identified sertraline, a common antidepressant, as a promising candidate. Sertraline, already approved for human use and with a known safety profile, had been shown in preclinical studies to inhibit SHMT2 activity. This concept of drug repurposing – using an existing drug for a new indication – is a highly attractive strategy in oncology, as it bypasses the lengthy and expensive drug development process, allowing for much faster clinical translation.
Supporting Data: The Dual Power of Proteomics and Chicken Egg Avatars
The success of this approach hinges on two sophisticated techniques: advanced proteomics and the innovative use of chicken egg avatars.
Proteomics: Unveiling the Tumour’s Functional Blueprint
Unlike genomics, which provides a static snapshot of a tumour’s genetic code, proteomics offers a dynamic view of the proteins actively expressed by the cancer cells. Proteins are complex molecules that can undergo various modifications after their initial synthesis (post-translational modifications), influencing their activity, location, and interactions with other proteins. These modifications, invisible to genomic sequencing, can profoundly alter cellular behavior and drug responsiveness.
"Think of genomics as reading the recipe book for a meal, while proteomics is analyzing the actual cooked dish," explains Dr. Georgina Barnabas, co-lead author of the study. "The recipe might tell you what ingredients are supposed to be there, but only by examining the final product can you truly understand how it was prepared, what went wrong if it’s not quite right, and what specific elements are most crucial for its function. In cancer, these ‘elements’ are often the very protein pathways that drive proliferation and survival."
The proteomic analysis performed by the UBC/BCCHR team involved sophisticated mass spectrometry techniques to identify and quantify thousands of proteins from the patient’s tumour sample. This high-resolution map revealed the over-reliance on SHMT2, a metabolic vulnerability that was not apparent from the genetic data. This demonstrated that proteomics can provide a deeper, more functional understanding of a tumour’s biology, opening up new avenues for targeted therapy when genomics hits a wall.
Chicken Egg Avatars: A Rapid, Personalized Drug Testing Platform
Once sertraline was identified as a potential SHMT2 inhibitor, the team faced the critical challenge of testing its efficacy against the patient’s unique tumour in a timely manner. Traditional preclinical models, such as patient-derived xenografts (PDX) in mice, can take months to establish and grow, a luxury often not afforded to pediatric patients with aggressive cancers. This is where the ingenious use of chicken egg avatars came into play.
The team employed a method that involves surgically grafting a small piece of the patient’s tumour onto the chorioallantoic membrane (CAM) of a fertilized chicken egg. The CAM is a highly vascularized extraembryonic membrane that supports the growth of the chick embryo. It provides a rich blood supply and a relatively immune-privileged environment, allowing the human tumour fragment to engraft and grow, replicating key features of the original tumour.
"This technique speeds up the process of evaluating a treatment option in a way that simply wouldn’t be possible with traditional methods," said Dr. Lim. "We could quickly confirm whether the drug we identified through proteomics could actually work for the patient’s tumour."
The advantages of the chicken egg avatar model are manifold:
- Speed: Tumours typically engraft and grow sufficiently for drug testing within 1-2 weeks, compared to several months for mouse models. This rapid turnaround is crucial for patients with aggressive, fast-progressing cancers.
- Cost-Effectiveness: Chicken eggs are significantly less expensive to acquire and maintain than laboratory mice, making this a more accessible platform.
- Ethical Considerations: While animal models are essential for biomedical research, chicken embryos are not considered sentient until late stages of development, presenting fewer ethical concerns than mammalian models for early-stage testing.
- Reproducibility: The standardized environment of the egg allows for consistent tumour growth and drug response testing.
- Preservation of Tumour Heterogeneity: The grafted tumour often retains the cellular architecture, microenvironment, and genetic/proteomic diversity of the original patient tumour, providing a more accurate representation for drug sensitivity testing.
The chicken egg avatars are a key component of the BRAvE initiative (Better Responses through Avatars and Evidence) at BCCHR, an innovative program specifically designed to bridge the gap between clinical care and research labs at the hospital. This initiative aims to rapidly translate research findings into actionable clinical strategies for children with hard-to-treat cancers.
After establishing the tumour avatar, the researchers administered sertraline to the eggs and observed a significant reduction in tumour growth, validating their hypothesis that targeting SHMT2 with this repurposed drug could indeed be an effective strategy for the patient.
Official Responses and Collaborative Validation
The compelling results from the combined proteomics and chicken egg avatar analysis were presented to a specialized panel of experts established by PROFYLE. This multidisciplinary tumour board, comprising oncologists, pathologists, geneticists, and research scientists from across Canada, meticulously reviewed all available data. Given the patient’s dire prognosis and the lack of other viable options, the panel unanimously endorsed sertraline as the best treatment option for the patient at that time, based on the strong preclinical evidence generated by the team.
This structured decision-making process, facilitated by the PROFYLE network, highlights the power of collaborative precision oncology. It ensures that the most cutting-edge research findings are rapidly vetted and translated into clinical recommendations, overcoming geographical and institutional barriers.
"The collaborative ecosystem forged by initiatives like PROFYLE and ACCESS is absolutely essential for these kinds of breakthroughs," states a spokesperson for the PROFYLE initiative. "No single institution or researcher can tackle the complexity of rare pediatric cancers alone. By pooling expertise, resources, and patient data across the country, we create a force multiplier that accelerates discovery and directly impacts patient care."
Implications: A Glimmer of Hope and a Path Forward
Following the expert panel’s recommendation, the patient began treatment with sertraline. The clinical outcome, while not a complete cure, was undeniably encouraging. The patient’s tumour growth significantly slowed, providing a much-needed reprieve and buying valuable time. This stabilization allowed the medical team to reassess and consider further treatment options, demonstrating the tangible impact of this personalized approach.
"While there is more work to be done, this study shows that our approach can deliver personalized treatment recommendations fast enough to actually help patients with rare and difficult-to-treat cancers," said Dr. Lange. "Slowing tumour growth in a patient who had exhausted all other options is a major victory. It offers precious time, improves quality of life, and opens windows for additional interventions."
The implications of this breakthrough extend far beyond this single patient. The successful integration of proteomics and chicken egg avatars represents a paradigm shift in precision oncology for several reasons:
- Expanded Therapeutic Options: For patients whose tumours do not present actionable genetic mutations, proteomics offers a crucial alternative pathway to uncover therapeutic targets. This significantly broadens the scope of personalized medicine.
- Accelerated Drug Discovery and Repurposing: The rapid turnaround time of the chicken egg avatar model enables quick screening of potential drugs, including existing approved medications, accelerating the identification of effective treatments.
- Real-Time Clinical Decision Making: The speed and accuracy of this integrated platform allow for personalized treatment recommendations to be generated within weeks, rather than months, making it truly "real-time" and clinically actionable for patients with aggressive cancers.
- Cost-Effectiveness: Utilizing repurposed drugs and a relatively inexpensive avatar model could make personalized cancer treatment more accessible and sustainable in the long run.
- Blueprint for Future Research: This study provides a robust framework that can be applied to other types of pediatric and even adult cancers, particularly those that are resistant to current therapies.
The research team now aims to expand this innovative method to a broader cohort of children across Canada, identifying effective treatments faster and more precisely. The next steps will involve further clinical validation, potentially through larger cohort studies or dedicated clinical trials, to formally integrate this approach into standard clinical practice. Additionally, researchers will continue to explore the full potential of proteomics, investigating other metabolic vulnerabilities and protein-protein interactions that could be targeted with novel or repurposed drugs.
This pan-Canadian triumph, born from the synergy of cutting-edge science, interdisciplinary collaboration, and a profound commitment to improving the lives of young cancer patients, offers a powerful testament to the enduring human spirit of innovation in the face of adversity. The humble chicken egg, combined with sophisticated protein analysis, has laid the groundwork for a future where personalized cancer treatment is not just a hope, but a rapid and tangible reality for every child in need.
About the Author
